Compare TKC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | EWTX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 2001 | 2021 |
| Metric | TKC | EWTX |
|---|---|---|
| Price | $4.82 | $46.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $7.38 | ★ $55.42 |
| AVG Volume (30 Days) | ★ 2.3M | 1.6M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.86 |
| Revenue | N/A | N/A |
| Revenue This Year | $30.23 | N/A |
| Revenue Next Year | $27.60 | N/A |
| P/E Ratio | $26.98 | ★ $5.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.46 | $19.76 |
| 52 Week High | $7.18 | $48.78 |
| Indicator | TKC | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 62.79 |
| Support Level | $4.49 | $37.22 |
| Resistance Level | $5.22 | $47.36 |
| Average True Range (ATR) | 0.09 | 3.14 |
| MACD | 0.04 | 0.94 |
| Stochastic Oscillator | 68.60 | 80.22 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.